Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.
暂无分享,去创建一个
Meindert Danhof | Oscar Della Pasqua | B. Ploeger | M. Danhof | R. Voskuyl | O. Della Pasqua | J. de Jongh | E. D. de Lange | Joost de Jongh | Rob A Voskuyl | Bart A Ploeger | Elizabeth C M De Lange | E. D. De Lange
[1] M. Danhof,et al. Pharmacokinetic-Pharmacodynamic Analysis of the EEG Effect of Alfentanil in Rats Followingβ-Funaltrexamine-Induced μOpioid Receptor “Knockdown”In Vivo , 2000, Pharmaceutical Research.
[2] J. Mandema,et al. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. , 1995, The Journal of pharmacology and experimental therapeutics.
[3] R. Bendayan,et al. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. , 2001, Pharmacological reviews.
[4] P. Gaillard,et al. The role of drug transporters at the blood-brain barrier. , 2003, Annual review of pharmacology and toxicology.
[5] M O Karlsson,et al. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. , 2000, The Journal of pharmacology and experimental therapeutics.
[6] D R Stanski,et al. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. , 1985, Anesthesiology.
[7] M. Danhof,et al. Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers , 2005, Pharmaceutical Research.
[8] F. Ehlert,et al. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. , 1988, Molecular pharmacology.
[9] W. Sieghart. GABAA receptors: ligand-gated Cl- ion channels modulated by multiple drug-binding sites. , 1992, Trends in pharmacological sciences.
[10] J. Nedelman,et al. Physiologically based pharmacokinetic modeling as a tool for drug development , 1995, Journal of Pharmacokinetics and Biopharmaceutics.
[11] Meindert Danhof,et al. Pharmacodynamic Analysis of the Interaction between Tiagabine and Midazolam with an Allosteric Model That Incorporates Signal Transduction , 2003, Epilepsia.
[12] M. Danhof,et al. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. , 1997, Journal of pharmacological and toxicological methods.
[13] G. Martin,et al. Estimation of agonist affinity and efficacy by direct, operational model-fitting. , 1990, Journal of pharmacological methods.
[14] M. Danhof,et al. Pharmacokinetic‐pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration , 1991, British journal of pharmacology.
[15] J. Black,et al. Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.
[16] M Danhof,et al. Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development , 1997, Clinical pharmacokinetics.
[17] Meindert Danhof,et al. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood–brain barrier , 1997, Brain Research Reviews.
[18] Kinetics of combined drug action , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[19] P Veng-Pedersen,et al. Pharmacodynamic system analysis of the biophase level predictor and the transduction function. , 1992, Journal of pharmaceutical sciences.
[20] M. Danhof,et al. Electroencephalogram Effect Measures and Relationships Between Pharmacokinetics and Pharmacodynamics of Centrally Acting Drugs , 1992, Clinical pharmacokinetics.
[21] P K Gessner,et al. Isobolographic analysis of interactions: an update on applications and utility. , 1995, Toxicology.
[22] J. Bergh,et al. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Malcolm Rowland,et al. Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002) , 2004, AAPS PharmSci.
[24] M Danhof,et al. Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[25] C. T. Viswanathan,et al. Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1992, Clinical pharmacology and therapeutics.
[26] J. A. Peters,et al. Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors. , 1997, Journal of medicinal chemistry.
[27] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[28] L. Peletier,et al. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT1A Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats , 2004, Journal of Pharmacology and Experimental Therapeutics.
[29] L B Sheiner,et al. Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model , 1984, Clinical pharmacology and therapeutics.
[30] M Danhof,et al. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration‐EEG effect relationship , 1992, British journal of pharmacology.
[31] R. Barlow,et al. The affinity and efficacy of onium salts on the frog rectus abdominis. , 1967, British journal of pharmacology and chemotherapy.
[32] M Danhof,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.
[33] D. Jonker,et al. A Pharmacokinetic‐pharmacodynamic Model for the Quantitative Prediction of Dofetilide Clinical QT Prolongation from Human Ether‐a‐go‐go‐related Gene Current Inhibition Data , 2005, Clinical pharmacology and therapeutics.
[34] Meindert Danhof,et al. A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. , 2002, The Journal of pharmacology and experimental therapeutics.
[35] William J Jusko,et al. Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[36] N. Modi,et al. A system approach to pharmacodynamics. Input-effect control system analysis of central nervous system effect of alfentanil. , 1993, Journal of pharmaceutical sciences.
[37] M. Danhof,et al. Influence of Different Fat Emulsion-Based Intravenous Formulations on the Pharmacokinetics and Pharmacodynamics of Propofol , 1998, Pharmaceutical Research.
[38] Ivan Nestorov,et al. Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.
[39] Berenbaum Mc. What is synergy? , 1989, Pharmacological reviews.
[40] Peter Veng-Pedersen,et al. Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions , 1991, Journal of Pharmacokinetics and Biopharmaceutics.
[41] M. Danhof,et al. The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. , 1999, Anesthesiology.
[42] Pharmacokinetic‐pharmacodynamic modelling of the anti‐lipolytic and anti‐ketotic effects of the adenosine A1‐receptor agonist N6‐(p‐sulphophenyl)adenosine in rats , 1997, British journal of pharmacology.
[43] W J Jusko,et al. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.
[44] T. Lewander,et al. Differential serotoninergic and dopaminergic activities of the (R)- and the (S)-enantiomers of 2-(di-n-propylamino)tetralin. , 1996, European journal of pharmacology.
[45] K. Zuideveld,et al. Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[46] M Danhof,et al. Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. , 1991, The Journal of pharmacology and experimental therapeutics.
[47] M Danhof,et al. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. , 1999, The Journal of pharmacology and experimental therapeutics.
[48] J. Šterc. Recent studies of hypothalamic function: K. Lederis and K.E. Cooper (Editors). Proceedings of the International Symposium, Calgary, 1973. (S. Karger, Basel, 1974, 434 p., 137 Fig., 17 Tables, DM 128.00, U.S. $49.25). , 1976 .
[49] M Danhof,et al. A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling. , 1991, Journal of pharmaceutical sciences.
[50] Meindert Danhof,et al. Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers , 1992, Clinical pharmacology and therapeutics.
[51] M. Danhof,et al. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. , 1992, The Journal of pharmacology and experimental therapeutics.
[52] Jin Y. Jin,et al. Modeling of Corticosteroid Pharmacogenomics in Rat Liver Using Gene Microarrays , 2003, Journal of Pharmacology and Experimental Therapeutics.
[53] M Danhof,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. , 1997, The Journal of pharmacology and experimental therapeutics.
[54] W. Greco,et al. The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.
[55] M. Danhof,et al. Quantification of the EEG Effect of Midazolam by Aperiodic Analysis in Volunteers , 1990, Clinical pharmacokinetics.
[56] M. Danhof,et al. 5.38 – Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling for the Prediction of In Vivo Drug Concentration–Effect Relationships – Application in Drug Candidate Selection and Lead Optimization , 2007 .
[57] E. Ekblad,et al. A model eliciting transient responses. , 1984, The American journal of physiology.
[58] N H Holford,et al. Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.
[59] M. Danhof,et al. Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo. , 1995, Life sciences.
[60] W. Jusko,et al. Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. , 2004, Journal of veterinary pharmacology and therapeutics.
[61] L. D. van de Kar,et al. Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist. , 1996, The Journal of pharmacology and experimental therapeutics.
[62] L. Peletier,et al. A Pharmacodynamic Turnover Model Capturing Asymmetric Circadian Baselines of Body Temperature, Heart Rate and Blood Pressure in Rats: Challenges in Terms of Tolerance and Animal-handling Effects , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[63] A. G. de Boer,et al. The role of P‐glycoprotein in blood‐brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (−/−) and mdr1a (+/+) mice , 1999, British Journal of Pharmacology.
[64] P H van der Graaf,et al. A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[65] R P STEPHENSON,et al. A MODIFICATION OF RECEPTOR THEORY , 1997, British journal of pharmacology and chemotherapy.
[66] L. Peletier,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats. , 2002, The Journal of pharmacology and experimental therapeutics.
[67] S L Shafer,et al. Response Surface Model for Anesthetic Drug Interactions , 2000, Anesthesiology.
[68] K. Brouwer,et al. Effect of GF120918, a Potent P-glycoprotein Inhibitor, on Morphine Pharmacokinetics and Pharmacodynamics in the Rat , 1998, Pharmaceutical Research.
[69] John Anthony Bauer,et al. Pharmacodynamic Models of Nitroglycerin-Induced Hemodynamic Tolerance in Experimental Heart Failure , 1994, Pharmaceutical Research.
[70] Lewis B. Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .
[71] M. Hammarlund-Udenaes. The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. , 2000, Advanced drug delivery reviews.
[72] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[73] S. Visser,et al. Rapid and long-lasting tolerance to clomethiazole-induced hypothermia in the rat. , 2005, European journal of pharmacology.
[74] K E Peace,et al. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[75] B. McEwen,et al. Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. , 2001, Annual review of pharmacology and toxicology.
[76] L. Paalzow,et al. Drug Equilibration Across the Blood—Brain Barrier-Pharmacokinetic Considerations Based on the Microdialysis Method , 1997, Pharmaceutical Research.
[77] Jin Y. Jin,et al. Receptor/Gene-Mediated Pharmacodynamic Effects of Methylprednisolone on Phosphoenolpyruvate Carboxykinase Regulation in Rat Liver , 2004, Journal of Pharmacology and Experimental Therapeutics.
[78] L. Peletier,et al. Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats , 2002, Journal of Pharmacology and Experimental Therapeutics.
[79] W. H. Carter. Relating isobolograms to response surfaces. , 1995, Toxicology.
[80] Ariens Ej,et al. A theoretical basis of molecular pharmacology. I. Interactions of one or two compounds with one receptor system. , 1956 .
[81] James C. Scott,et al. Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. , 1991, Anesthesiology.
[82] M. Danhof,et al. Pharmacokinetic‐pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation , 1998, British journal of pharmacology.
[83] Meindert Danhof,et al. Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting , 2002, Clinical pharmacokinetics.
[84] L B Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models , 1986, Clinical pharmacology and therapeutics.
[85] E. Zeisberger. Chapter 10 Biogenic amines and thermoregulatory changes , 1998 .
[86] M. Danhof,et al. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.
[87] J. Steimer,et al. A mathematical model for dynamics of cardiovascular drug action: Application to intravenous dihydropyridines in healthy volunteers , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[88] Meindert Danhof,et al. Disease System Analysis: Basic Disease Progression Models in Degenerative Disease , 2005, Pharmaceutical Research.
[89] M. Danhof,et al. Pharmacokinetic-Pharmacodynamic Modelling of the Interaction between Flumazenil and Midazolam in Volunteers by Aperiodic EEG Analysis , 1991, Clinical pharmacokinetics.
[90] M. Danhof,et al. Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. , 1994, The Journal of pharmacology and experimental therapeutics.
[91] M. Danhof,et al. Partial agonism of the nonselective adenosine receptor agonist 8-butylaminoadenosine at the A1 receptor in vivo. , 1996, Journal of Pharmacology and Experimental Therapeutics.
[92] M. Danhof,et al. Selectivity of action of 8‐alkylamino analogues of N6‐cyclopentyladenosine in vivo: haemodynamic versus anti‐lipolytic responses in rats , 1998, British journal of pharmacology.
[93] Malcolm Rowland,et al. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). , 2004, AAPS pharmSci.
[94] L. Sheiner,et al. Pharmacokinetics and Pharmacodynamics of d-Tubocurarine during Nitrous Oxide–Narcotic and Halothane Anesthesia in Man , 1979 .
[95] D J Greenblatt,et al. Pharmacokinetic-Pharmacodynamic Relationships For Benzodiazepines , 1996, Clinical pharmacokinetics.
[96] M. Danhof,et al. Physiological Indirect Effect Modeling of the Antilipolytic Effects of Adenosine A1-Receptor Agonists , 1997, Journal of Pharmacokinetics and Biopharmaceutics.
[97] M. Danhof,et al. Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6‐cyclopentyladenosine and 8‐cyclopentyltheophylline , 1995, British journal of pharmacology.
[98] Patrick Poulin,et al. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. , 2002, Journal of pharmaceutical sciences.
[99] M. Danhof,et al. Mechanism-Based Pharmacodynamic Modeling of the Interaction of Midazolam, Bretazenil, and Zolpidem with Ethanol , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[100] M. R. Bouw,et al. Blood‐brain barrier transport and brain distribution of morphine‐6‐glucuronide in relation to the antinociceptive effect in rats – pharmacokinetic/pharmacodynamic modelling , 2001, British journal of pharmacology.
[101] L. Peletier,et al. Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan. , 2002, European journal of pharmacology.
[102] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[103] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[104] L. Peletier,et al. Neuroactive Steroids Differ in Potency but Not in Intrinsic Efficacy at the GABAA Receptor in Vivo , 2002, Journal of Pharmacology and Experimental Therapeutics.
[105] M. Danhof,et al. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. , 2005, Pharmacology & therapeutics.
[106] M. Danhof,et al. Deoxyribose analogues of N6‐cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo , 1995, British journal of pharmacology.
[107] W. Winter,et al. A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[108] J. Urquhart,et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans , 1987, Clinical pharmacology and therapeutics.
[109] R. Ramakrishnan,et al. Fifth-Generation Model for Corticosteroid Pharmacodynamics: Application to Steady-State Receptor Down-Regulation and Enzyme Induction Patterns During Seven-Day Continuous Infusion of Methylprednisolone in Rats , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[110] M Danhof,et al. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalogram Effects of GABAA Receptor Modulators: In Vitro-in Vivo Correlations , 2003, Journal of Pharmacology and Experimental Therapeutics.
[111] Varun Garg,et al. Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[112] Adriaan Cleton,et al. Application of a Combined “Effect Compartment/Indirect Response Model” to the Central Nervous System Effects of Tiagabine in the Rat , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[113] Juliana Barr,et al. Remifentanil Versus Alfentanil: Comparative Pharmacokinetics and Pharmacodynamics in Healthy Adult Male Volunteers , 1996, Anesthesiology.
[114] A. Schinkel,et al. Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3) , 2004, Journal of Pharmacology and Experimental Therapeutics.
[115] W. Haefely,et al. The multiplicity of actions of benzodiazepine receptor ligands. , 1993, Canadian journal of psychiatry. Revue canadienne de psychiatrie.